NewAmsterdam Pharma Co N.V. (NAMS) Profit Margins
Over the twelve months to 2026-06-30, NewAmsterdam Pharma Co N.V. (NAMS) had operating margin -3432.2%, net margin -3644.2%, free cash flow margin -2018.3%, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
NAMSNewAmsterdam Pharma Co N.V.Follow NAMS — free
—
Price chart with a free account
- Market cap
- 2.4B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 11 Nov, in 18 days
| Line | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|
| Operating margin | -1298.6% | -386.9% | -1002.9% | -3432.2% | |
| Net margin | -1255.8% | -530.3% | -905.7% | -3644.2% | |
| FCF margin | -1002.4% | -349.5% | -657.8% | -2018.3% |
USD millions · SEC XBRL
NewAmsterdam Pharma Co N.V. — questions
- What is NewAmsterdam Pharma Co N.V.'s operating margin?
- -3432.2% over the twelve months to 2026-06-30.
- What is NewAmsterdam Pharma Co N.V.'s net profit margin?
- -3644.2% over the twelve months to 2026-06-30.
Every figure on this page comes from NewAmsterdam Pharma Co N.V.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.